title: Co-signaling molecules in psoriasis pathogenesis: implications for targeted therapy.
abstract: Psoriasis is a T cell-dependent immune-mediated disease of the skin and joints. It is clear that co-stimulatory and co-inhibitory molecules (currently named co-signaling molecules collectively) synergize with TCR signaling to promote or inhibit T cell activation and function. In recent years, enthusiasm in the field of co-signaling research has been fueled by the success of co-stimulatory and co-inhibitory immunotherapy for the treatment of human diseases. This review outlines the involvement of several sets of co-signaling molecules in the immunopathogenesis of psoriasis. We then describe the relevant preclinical studies and summarize recent clinical findings on targeting these molecules for the treatment of psoriasis.
authors: Department of Dermatology, The First Affiliated Hospital of Dalian Medical University, 222 Zhong Shan Lu, Dalian 116011, China. Electronic address: lxiran02@aliyun.com.
authors: Xiran
authors: X
authors: Lin
authors: Department of Dermatology, The Second Affiliated Hospital of Dalian Medical University, 467 Zhong Shan Lu, Dalian 116027, China.
authors: Tian
authors: T
authors: Huang
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007167:Immunotherapy; D008213:Lymphocyte Activation; D058990:Molecular Targeted Therapy; D011565:Psoriasis / Q000188:drug therapy / Q000276:immunology*; D020239:Receptor Cross-Talk; D011948:Receptors, Antigen, T-Cell; D015398:Signal Transduction; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D011948:Receptors, Antigen, T-Cell
keywords: Co-signaling molecules; Psoriasis; T cell activation; Therapeutic targets